Zobrazeno 1 - 10
of 153
pro vyhledávání: '"Paul Balmer"'
Autor:
David E. Bloom, Paolo Bonanni, Federico Martinón-Torres, Peter C. Richmond, Marco A. P. Safadi, David M. Salisbury, Apostolos Charos, Katharina Schley, Jamie Findlow, Paul Balmer
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 12, Pp 2649-2663 (2023)
Abstract The global invasive meningococcal disease (IMD) landscape changed considerably during the COVID-19 pandemic, as evidenced by decreased incidence rates due to COVID-19 mitigation measures, such as limited social contact, physical distancing,
Externí odkaz:
https://doaj.org/article/c523a0068eb04bd1a5c9763bb74ef4ba
Autor:
Rodolfo Villena, Paula Kriz, Myint Tin Tin Htar, Cindy Burman, Jamie Findlow, Paul Balmer, Luis Jodar
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 2 (2023)
In response to escalating cases of serogroup W (MenW) invasive meningococcal disease (IMD), multiple countries introduced quadrivalent conjugate MenACWY vaccines into their national immunization programs (NIPs). Here, we summarize the real-world impa
Externí odkaz:
https://doaj.org/article/d2ffd0826ad547fa9d46452b36f52505
Autor:
Myint Tin Tin Htar, Sally Jackson, Paul Balmer, Lidia Cristina Serra, Andrew Vyse, Mary Slack, Margarita Riera-Montes, David L. Swerdlow, Jamie Findlow
Publikováno v:
BMC Public Health, Vol 20, Iss 1, Pp 1-15 (2020)
Abstract Background Monovalent meningococcal C conjugate vaccine (MCCV) was introduced into the routine immunization program in many countries in Europe and worldwide following the emergence of meningococcal serogroup C (MenC) in the late 1990s. This
Externí odkaz:
https://doaj.org/article/f10550c29f1f4c9989fe1bc2c6c4e7ff
Autor:
Johannes Beeslaar, Paula Peyrani, Judith Absalon, Jason Maguire, Joseph Eiden, Paul Balmer, Roger Maansson, John L. Perez
Publikováno v:
Infectious Diseases and Therapy, Vol 9, Iss 3, Pp 625-639 (2020)
Abstract Introduction An extensive clinical development program showed that the meningococcal serogroup B-factor H binding protein (MenB-FHbp) vaccine affords protection against MenB disease for adolescents and adults. Data were pooled from multiple
Externí odkaz:
https://doaj.org/article/6535a2f816844600a07e80aafa81a894
Autor:
Johannes Beeslaar, Judith Absalon, Annaliesa S. Anderson, Joseph J. Eiden, Paul Balmer, Shannon L. Harris, Thomas R. Jones, Robert E. O’Neill, Jean-Louis Pregaldien, David Radley, Roger Maansson, John Ginis, Amit Srivastava, John L. Perez
Publikováno v:
Infectious Diseases and Therapy, Vol 9, Iss 3, Pp 641-656 (2020)
Abstract Introduction Two phase 3 studies in adolescents and young adults demonstrated that MenB-FHbp, a meningococcal serogroup B (MenB) vaccine, elicits protective immune responses after 2 or 3 doses based on serum bactericidal antibody assays usin
Externí odkaz:
https://doaj.org/article/563c1eec3812425a983cfc833396fcc9
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 10, Pp 2491-2500 (2019)
Invasive meningococcal disease is rare and potentially devastating but often vaccine-preventable. Evaluation of meningococcal vaccine effectiveness is impractical owing to relatively low disease incidence; protection is therefore estimated using seru
Externí odkaz:
https://doaj.org/article/e55c5a0b8bef424ca9867453665439bb
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 2, Pp 459-469 (2019)
Invasive meningococcal disease (IMD) caused by Neisseria meningitidis is characterized by high mortality and morbidity. While IMD incidence peaks in both infants and adolescents/young adults, carriage rates are often highest in the latter age groups,
Externí odkaz:
https://doaj.org/article/b2b094ac9560440486a9b0b829484c8a
Publikováno v:
Vaccine. 41:2729-2733
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0c57e9f3a80e0305d8be796af104bae
https://doi.org/10.1016/j.vaccine.2023.02.078
https://doi.org/10.1016/j.vaccine.2023.02.078
Autor:
Helen S Marshall, Timo Vesikari, Peter C Richmond, Jacek Wysocki, Leszek Szenborn, Johannes Beeslaar, Jason D Maguire, Paul Balmer, Robert O'Neill, Annaliesa S Anderson, Jean-Louis Prégaldien, Roger Maansson, Han-Qing Jiang, John L Perez
Publikováno v:
The Lancet Infectious Diseases. 23:103-116
The meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) is licensed for use in children aged 10 years or older for protection against invasive serogroup B meningococcal disease. Because young children are at increased risk of invas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ca3643e8720a5702d60ca0f95864049
https://doi.org/10.1016/s1473-3099(22)00424-8
https://doi.org/10.1016/s1473-3099(22)00424-8
Publikováno v:
Frontiers in Microbiology, Vol 11 (2020)
Externí odkaz:
https://doaj.org/article/805e2ecb69e348228a7edcaa05b35cc7